Rosiglitazone reduces the evolution of experimental periodontitis in the rat

R. Di Paola, E. Mazzon, D. Maiere, D. Zito, D. Britti, M. De Majo, T. Genovese, S. Cuzzocrea

Research output: Contribution to journalArticlepeer-review


The peroxisome proliferator-activated receptor-γ (PPAR-γ) receptor appears to play a pivotal role in the regulation of cellular proliferation and inflammation. Recent evidence also suggests that rosiglitazone, a PPAR-γ agonist, reduces acute and chronic inflammation. We hypothesized that rosiglitazone would attenuate periodontal inflammation. In the present study, we investigated the effects of rosiglitazone in a rat model of ligature-induced periodontitis. At day 8, ligation significantly induced an increase in neutrophil infiltration, as well as of gingivomucosal tissue expression of iNOS, nitrotyrosine formation, and poly (ADP-ribose) polymerase activation. Ligation significantly increased Evans blue extravasation in gingivomucosal tissue and alveolar bone destruction. Intraperitoneal injection of rosiglitazone (10 mg/kg 10% DMSO daily for 8 days) significantly decreased all of the parameters of inflammation, as described above. Analysis of these data demonstrated that rosiglitazone exerted an anti-inflammatory role during experimental periodontitis, and was able to ameliorate the tissue damage associated with ligature-induced periodontitis.

Original languageEnglish
Pages (from-to)156-161
Number of pages6
JournalJournal of Dental Research
Issue number2
Publication statusPublished - Feb 2006


  • Alveolar bone loss
  • Periodontal diseases
  • Peroxisome proliferator-activated receptor-γ ligand
  • Reactive oxygen species
  • Rosiglitazone

ASJC Scopus subject areas

  • Dentistry(all)


Dive into the research topics of 'Rosiglitazone reduces the evolution of experimental periodontitis in the rat'. Together they form a unique fingerprint.

Cite this